Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C99H140N20O17 |
Molecular Weight | 1882.2947 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=C7C=CC=C8)C(=O)NCCO
InChI
InChIKey=ZWCXYZRRTRDGQE-LUPIJMBPSA-N
InChI=1S/C99H140N20O17/c1-51(2)37-73(109-86(123)59(17)107-81(122)49-105-96(133)82(55(9)10)106-50-121)89(126)108-60(18)87(124)117-84(57(13)14)98(135)119-85(58(15)16)99(136)118-83(56(11)12)97(134)116-80(44-64-48-104-72-34-26-22-30-68(64)72)95(132)112-76(40-54(7)8)92(129)115-79(43-63-47-103-71-33-25-21-29-67(63)71)94(131)111-75(39-53(5)6)91(128)114-78(42-62-46-102-70-32-24-20-28-66(62)70)93(130)110-74(38-52(3)4)90(127)113-77(88(125)100-35-36-120)41-61-45-101-69-31-23-19-27-65(61)69/h19-34,45-48,50-60,73-80,82-85,101-104,120H,35-44,49H2,1-18H3,(H,100,125)(H,105,133)(H,106,121)(H,107,122)(H,108,126)(H,109,123)(H,110,130)(H,111,131)(H,112,132)(H,113,127)(H,114,128)(H,115,129)(H,116,134)(H,117,124)(H,118,136)(H,119,135)/t59-,60-,73+,74+,75+,76+,77-,78-,79-,80-,82-,83+,84+,85-/m0/s1
Molecular Formula | C99H140N20O17 |
Molecular Weight | 1882.2947 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 9 |
Optical Activity | UNSPECIFIED |
Linear gramicidin is a hydrophobic antibiotic polypeptide composed of 15 hydrophobic amino acids in D- and L-alternate conformers with the following sequence: formyl-L-X-gly-L-ala-D-leu-L-ala-D-val-L-val-D-val-L-trp-D-leu-Ltrp-D-leu-L-trp-D-leu-L-trp-ethanolamine where X represents either valine or isoleucine. Whether amino acid 11 is tryptophan, phenylalanine, or tyrosine, gramicidins are called A, B, or C, respectively. A mixture of three pairs of antibacterial substances (Gramicidin A, B, and C) is also called Gramicidin D and is produced by the growth of Bacillus brevis Dubos (Fam. Bacillaceae). Gramicidin is bactericidal for a variety of gram-positive organisms. It increases the permeability of the bacterial cell membrane to inorganic cations by forming a network of channels through the normal lipid bilayer of the membrane. Gramicidin is used in the combination with neomycin sulfate and polymyxin B sulfate (NEOSPORIN®) for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. Launch Date1955 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. Launch Date1955 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. Launch Date1955 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. Launch Date1955 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis. Launch Date1955 |
Sample Use Guides
Instill one or two drops of NEOSPORIN® into the affected eye every 4 hours for 7 to 10 days. In severe infections, dosage may be increased to as much as two drops every hour.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/56113
The K+ transport in erythrocytes induced by gramicidin A or valinomycin is a first-order reaction. The activation energy of the induced transport is low and amounts to 6 and 10 kcal/mole, respectively. The indirect method for calculation of the driving force of diffusion, c, is given; in pig erythrocytes, the c value for gramicidin A is 21.7, and for valinomycin 35.4 mM-KCl. The gramicidin A-induced transport corresponds to that of a single gramicidin channel, and not to the multichannel transport observed in the model systems.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:13:09 GMT 2023
by
admin
on
Fri Dec 15 16:13:09 GMT 2023
|
Record UNII |
93AG3Q5T2V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4419-81-2
Created by
admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
|
PRIMARY | |||
|
DTXSID80891352
Created by
admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
|
PRIMARY | |||
|
16132269
Created by
admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
|
PRIMARY | |||
|
93AG3Q5T2V
Created by
admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
|
PRIMARY |